Individualization of the subcutaneous amifostine dose during hypofractionated/accelerated radiotherapy

Anticancer Research

Volumn 26, Issue 3 B, 2006, Pages 2437-2443

  Koukourakis, Michael I ^a,b   Abatzoglou, Ioannis ^a   Sivridis, Leonidas ^a   Tsarkatsi, Maria ^a   Delidou, Helen ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b DUTh ^*  (Greece)

Author keywords

Acceleration; Amifostine dose; Hypofractionation; Radiotherapy; Subcutaneous

Indexed keywords

AMIFOSTINE; DEXAMETHASONE;

ALGORITHM; ARTICLE; BREAST CANCER; CANCER PATIENT; CELL PROTECTION; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; ERYTHEMA; FATIGUE; FEVER; HEAD AND NECK CANCER; HEADACHE; HUMAN; HUMAN CELL; HYPOTENSION; LUNG CANCER; NAUSEA; NAUSEA AND VOMITING; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; RATING SCALE; RECTUM CANCER; SIDE EFFECT; SWEATING; SYMPTOMATOLOGY; SYNCOPE; URINARY TRACT CANCER;

ALGORITHMS; AMIFOSTINE; DEXAMETHASONE; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; INDIVIDUALITY; INJECTIONS, SUBCUTANEOUS; NEOPLASMS; RADIATION-PROTECTIVE AGENTS;

EID: 33745552177     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Brizel DM, Wasserman TH, Henke M et al: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18: 3339-3345, 2000.
2. Werner-Wasik M, Axelrod RS, Friedland DP et al: Preliminary report on reduction of esophagitis by amifostine in patients with non-small-cell lung cancer treated with chemoradiotherapy. Clin Lung Cancer 2: 284-289, 2001.
3. Vacha P, Fehlauer F, Mahlmann B et al: Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection? Strahlenther Onkol 179: 385-389, 2003.
4. Antonadou D, Petridis A, Synodinou M et al: Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer. Semin Oncol 30(Suppl): S2-9, 2003.
5. Athanassiou H, Antonadou D, Coliarakis N et al: Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial. Int J Radiat Oncol Biol Phys 56:1154-1160, 2003.
6. Antonadou D, Pepelassi M, Synodinou M et al: Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 52: 739-747, 2002.
7. Komaki R, Lee JS, Milas L et al: Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58: 1369-1377, 2004.
8. Vujaskovic Z, Feng QF, Rabbani ZN et al: Assessment of the protective effect of amifostine on radiation-induced pulmonary toxicity. Exp Lung Res 28: 577-590, 2002.
9. Brizel DM and Overgaard J: Does amifostine have a role in chemoradiation treatment? Lancet Oncol 4: 378-381, 2003.
10. Lindegaard JC and Grau C: Has the outlook improved for amifostine as a clinical radioprotector? Radiother Oncol 57: 113-118, 2000.
11. Koukourakis MI: Amifostine in clinical oncology: current use and future applications. Anticancer Drugs 13: 181-209, 2002.
12. Koukourakis MI: Amifostine: is there evidence of tumour protection? Semin Oncol 30(Suppl): S18-30, 2003.
13. Mantovani G, Maccio A, Madeddu C et al: Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. J Mol Med 81: 664-673, 2003.
14. Provinciali M, Ciavattini A, Di Stefano G et al: In vivo amifostine (WR-2721) prevents chemotherapy-induced apoptosis of peripheral blood lymphocytes from cancer patients. Life Sci 64: 1525-1532, 1999.
15. Koukourakis MI, Ktenidou-Kartali S, Bourikas G et al: Amifostine protects lymphocytes during radiotherapy and stimulates expansion of the CD95/Fas and CD31 expressing T-cells, in breast cancer patients. Cancer Immunol Immunother 52: 127-131, 2003.
16. Shaw LM, Bonner HS, Schuchter L et al: Pharmacokinetics of amifostine: effects of dose and method of administration. Sem Oncol 26(suppl): S34-36, 1999.
17. Cassatt DR, Fazenbaker CA, Kifle G and Bachy CM: Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine. Semin Oncol 29(Suppl): S2-8, 2002.
18. Koukourakis MI and Yannakakis D: High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae. Anticancer Res 21: 2973-2978, 2001.
19. Koukourakis MI, Giatromanolaki A, Kouroussis C et al: Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients. Int J Radiat Oncol Biol Phys 52: 144-155, 2002.
20. Macejewski B, Taylor JM and Wither HR: Alpha/beta and the importance of the size of dose per fraction for late complications in the supraglottic larynx. Radiother Oncol 7: 323-326, 1986.
21. Koukourakis MI and Damilakis J: LQ-based model for biological radiotherapy planning. Med Dosim 19: 269-277, 1994.
22. Koukourakis MI, Kyrias G, Kakolyris S et al: Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol 18: 2226-2233, 2000.
23. Koukourakis MI, Simopoulos C, Minopoulos G et al: Amifostine before chemotherapy: improved tolerance profile of the subcutaneous over the intravenous route. Clin Cancer Res 9: 3288-3293, 2003.
24. Anne PR: Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. Semin Oncol 29(Suppl): 80-83, 2002.
25. Bardet E, Martin L, Calais G et al: Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumours treated by external radiotherapy. Semin Oncol 29(Suppl): 57-60, 2002.
26. Bachy CM, Fazenbaker CA, Kifle G et al: Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys. Oncology 67: 187-193, 2004.
27. Cassatt DR, Fazenbaker CA, Kifle G and Bachy CM: Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model. Int J Radiat Oncol Biol Phys 57: 794-802, 2003.
28. Cassait DR, Fazenbaker CA, Kifle G and Bachy CM: Effects of dose and schedule on the efficacy of ethyol: preclinical studies. Semin Oncol 30(Suppl): S31-39, 2003.
29. Bourhis J, De Crevoisier R, Abdulkarim B et al: A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 46: 1105-1108, 2000.
30. Lyass O, Lotem M, Edelmann D et al: Protective effect of amifostine (AMF) on doxil/caelyx-induced palmar-plantar erythrodysesthesia (PPE) in patients (PTS) with advanced cancer. Proc Am Soc Clin Oncol 20: 99b, Abstract 2148, 2001.